Exosomes derived from interleukin-10-treated dendritic cells can inhibit trinitrobenzene sulfonic acid-induced rat colitis

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 10, 2010, Pages 1168-1177

  Yang, Xiaojun ^a   Meng, Song ^a   Jiang, Hong ^a   Chen, Tao ^a   Wu, Wenxi ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Dendritic cell; exosomes; inflammatory bowel disease; interleukin 10

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; DENDRITIC CELL; EXOSOME; HISTOPATHOLOGY; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE;

ANIMALS; COLITIS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; EXOSOMES; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2; MALE; MUCOUS MEMBRANE; RATS; RATS, WISTAR; RNA, MESSENGER; T-LYMPHOCYTES; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956577890     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.490596     Document Type: Article

References (30)

1. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010;10:170-181
2. Kim KN, Watanabe S, Ma Y, Thornton S, Giannini EH, Hirsch R. Viral IL-10 and soluble TNF receptor act syner-gistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer. J Immunol 2000;164: 1576-1581
3. Whalen JD, Lechman EL, Carlos CA, Weiss K, Kovesdi I, Glorioso JC. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 1999;162:3625-3632
4. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem 1987;262:9412-9420
5. Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 2001; 166:7309-7318
6. Vincent-Schneider H, Stumptner-Cuvelette P, Lankar D, PainS,RaposoG,BenarochP,BonnerotC.Exosomesbearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int Immunol 2002;14:713-722
7. Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005;3:9.
8. Peche H, Heslan M, Usal C, Amigorena S, Cuturi MC. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection. Transplantation 2003;76:1503-1510
9. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-1517
10. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3: 521-533
11. Neurath M, Fuss I, Strober W. TNBS-colitis. Int Rev Immunol 2000;19:51-62.
12. Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, et al. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol 2005;174:6440-6448
13. Beriou G, Peche H, Guillonneau C, Merieau E, Cuturi MC. Donor-specific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immu-nosuppression. Transplantation 2005;79:969-972
14. Kim SH, Bianco NR, Shufesky WJ, Morelli AE, Robbins PD. Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4. J Immunol 2007;179:2242-2249
15. Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996;26:934-938
16. Hartmann G, Bidlingmaier C, Siegmund B, Albrich S, Schulze J, Tschoep K, et al. Specific type IV phosphodies-terase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther 2000;292:22-30.
17. Wallace JL, Keenan CM. An orally active inhibitor of leu-kotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol 1990;258:G527-34.
18. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999;190:995-1004.
19. Boirivant M, Fuss IJ, Chu A, Strober W. Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998;188: 1929-1939
20. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neu-trophil content with an enzyme marker. J Invest Dermatol 1982;78:206-209
21. Voisine C, Hubert FX, Trinite B, Heslan M, Josien R. Two phenotypically distinct subsets of spleen dendritic cells in rats exhibit different cytokine production and T cell stimulatory activity. J Immunol 2002;169:2284-2291
22. Van der Heijden PJ, Stok W. Improved procedure for the isolation of functionally active lymphoid cells from the murine intestine. J Immunol Methods 1987;103:161-167
23. Faulkner L, Buchan G, Baird M. Interleukin-10 does not affect phagocytosis of particulate antigen by bone marrow-derived dendritic cells but does impair antigen presentation. Immunology 2000;99:523-531
24. Buelens C, Willems F, Delvaux A, Pierard G, Delville JP, Velu T, Goldman M. Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol 1995;25: 2668-2672
25. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protocol 2007;2:541-546
26. Ruffner MA, Kim SH, Bianco NR, Francisco LM, Sharpe AH, Robbins PD. B7-1/2, but not PD-L1/2 molecules, are required on IL-10-treated tolerogenic DC and DC-derived exosomes for in vivo function. Eur J Immunol 2009;39:3084-3090
27. Delcayre A, Estelles A, Sperinde J, et al. Exosome Display technology: applications to the development of new diagnostics and therapeutics. Blood Cells Mol Dis 2005;35:158-168
28. Daniel C, Sartory N, Zahn N, Geisslinger G, Radeke HH, Stein JM. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol 2007;178:2458-2468
29. Liu H, Hu B, Xu D, Liew FY. CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4. J Immunol 2003;171:5012-5017
30. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302.